Low red blood cell levels of deglycating enzymes in colorectal cancer patients

World Journal of Gastroenterology

Volumn 17, Issue 3, 2011, Pages 329-333

  Notarnicola, Maria ^a   Caruso, Maria Gabriella ^a   Tutino, Valeria ^a   Guerra, Vito ^a   Misciagna, Giovanni ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Colorectal cancer; Enzymatic activity; Fruc tosamine 3 kinase; Glycation; Glyoxalase I

Indexed keywords

ERYTHROCYTE ENZYME; FRUCTOSAMINE 3 KINASE; LACTOYLGLUTATHIONE LYASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE; ERYTHROCYTE DISORDER; FEMALE; HUMAN; HUMAN CELL; MALE; RADIOMETRY; SPECTROPHOTOMETRY;

EID: 79955749210     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i3.329     Document Type: Article

References (28)

1. Thornalley PJ. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 2003; 31: 1341-1342
2. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996; 27: 565-573
3. Ramasamy R, Yan SF, Schmidt AM. Methylglyoxal comes of AGE. Cell 2006; 124: 258-260
4. Okado A, Kawasaki Y, Hasuike Y, Takahashi M, Teshima T, Fujii J, Taniguchi N. Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem Biophys Res Commun 1996; 225: 219-224
5. Hsuuw YD, Chang CK, Chan WH, Yu JS. Curcumin prevents methylglyoxal-induced oxidative stress and apoptosis in mouse embryonic stem cells and blastocysts. J Cell Physiol 2005; 205: 379-386
6. Strzinek RA, Vela GR, Scholes VE, Norton SJ. Further studies on liver glyoxalase activity in mice bearing lymphosar-coma. Cancer Res 1970; 30: 334-337
7. Együd LG, Szent-Györgyi A. On the regulation of cell division. Proc Natl Acad Sci USA 1966; 56: 203-207
8. Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, Talesa V. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 2001; 66: 67-72
9. Mearini E, Romani R, Mearini L, Antognelli C, Zucchi A, Baroni T, Porena M, Talesa VN. Differing expression of enzymes of the glyoxalase system in superfcial and invasive bladder carcinomas. Eur J Cancer 2002; 38: 1946-1950
10. Davidson SD, Cherry JP, Choudhury MS, Tazaki H, Mal-louh C, Konno S. Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. J Urol 1999; 161: 690-691
11. Antognelli C, Baldracchini F, Talesa VN, Costantini E, Zuc-chi A, Mearini E. Overexpression of glyoxalase system enzymes in human kidney tumor. Cancer J 2006; 12: 222-228
12. Dawnay A, Millar DJ. The pathogenesis and consequences of AGE formation in uraemia and its treatment. Cell Mol Biol (Noisy-le-grand) 1998; 44: 1081-1094
13. Delpierre G, Van Schaftingen E. Fructosamine 3-kinase, an enzyme involved in protein deglycation. Biochem Soc Trans 2003; 31: 1354-1357
14. Delpierre G, Rider MH, Collard F, Stroobant V, Vanstapel F, Santos H, Van Schaftingen E. Identifcation, cloning, and heterologous expression of a mammalian fructosamine-3-kinase. Diabetes 2000; 49: 1627-1634
15. Caruso MG, Notarnicola M, Altomare DF, Misciagna G. Gene expression of fructosamine 3 kinase in patients with colorectal cancer. Oncology 2007; 73: 72-75
16. Notarnicola M, Caruso MG, Tutino V, Guerra V, Frisullo S, Altomare DF, Misciagna G. Reduced fructosamine-3-kinase activity and its mRNA in human distal colorectal carcinoma. Genes Nutr 2010; 5: 257-262
17. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460
18. Antognelli C, Del Buono C, Baldracchini F, Talesa V, Cottini E, Brancadoro C, Zucchi A, Mearini E. Alteration of glyoxa-lase genes expression in response to testosterone in LNCaP and PC3 human prostate cancer cells. Cancer Biol Ther 2007; 6: 1880-1888
19. Misciagna G, De Michele G, Guerra V, Cisternino AM, Di Leo A, Freudenheim JL. Serum fructosamine and colorectal adenomas. Eur J Epidemiol 2004; 19: 425-432
20. Thornalley PJ. Modifcation of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 1988; 254: 751-755
21. Cohen PP. Glyoxalase activity of liver from rats fed p-di-methylaminoazobenzene. Cancer Res 1945; 5: 626-630
22. Cohen PP, Sober EK. Glyoxalase activity of erythrocytes from cancerous rats and human subjects. Cancer Res 1945; 5: 631-632
23. Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crinò L, Barberini F, Rulli A. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 2009; 9: 115
24. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-1123
25. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009; 15: 5141-5148
26. Tabuchi M, Kitayama J, Nagawa H. Hyperglycemia and hypertriglyceridemia may associate with the adenoma-carcinoma transition in colorectal epithelial cells. J Gastroenterol Hepatol 2008; 23: 985-987
27. Monnier VM, Sell DR, Dai Z, Nemet I, Collard F, Zhang J. The role of the amadori product in the complications of diabetes. Ann N Y Acad Sci 2008; 1126: 81-88
28. Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005; 65: 1013-1015